Sanofi investigated over epilepsy drug linked to birth defects
Share:
PARIS (Reuters) - French healthcare company Sanofi said on Tuesday it was being investigated over Depakine, an epilepsy drug which caused birth malfunctions and slow neurological development when taken during pregnancy.The Paris prosecutor launched a preliminary investigation into the authorisation and marketing of Depakine in October 2016 after French social affairs inspection agency IGAS criticised the slow response of French health authorities and Sanofi over the risks related to the drug..